Oxytocin Nasal Spray

Oxytocin is an endogenous hormone of nine amino acids, made in the hypothalamus and released into the blood from the posterior pituitary. Vincent du Vigneaud worked out its sequence in 1953 and made it the first peptide hormone ever synthesised, which earned him the 1955 Nobel Prize in Chemistry. Oxytocin differs from vasopressin, the water-balance hormone, by only two amino acids. Classically it belongs to obstetrics (contractions, milk let-down); it became famous in 2005 when a Zurich group showed that a nasal spray increased trust in a game played for money (Kosfeld and colleagues, Nature 2005). Since then newspapers call it the "cuddle hormone". With several hundred studies, nasal oxytocin is one of the most investigated peptides in social neuroscience.

This variant is the finished nasal spray: 10mg of oxytocin dissolved in 5ml of saline (NaCl) plus 0.4ml of bacteriostatic water, 5.4ml in total, which gives 1.85mg per ml. The pump delivers 0.1ml per spray, so 185mcg or about 0.19mg. On paper the bottle holds 54 sprays. After priming the pump about 50 remain usable. No mixing of your own, no syringe, no unit maths: the spray is filled fresh after you order and ships as an express item. If you prefer working with the vial, the Oxytocin Acetate entry has the calculator.

One thing you need to know: oxytocin is measured in international units. 1 IU is roughly 1.67mcg. One spray from this bottle therefore contains about 111 IU, while almost all human studies use 24 IU per dose, i.e. 0.04mg. A single spray is almost five times the classic study dose. That is why the TPD line ends at one spray per day and has no second step.

This information is for research and educational purposes only. No medical advice.

Oxytocin binds the oxytocin receptor (OXTR), a G-protein-coupled receptor. Peripherally it sits on the muscle of the uterus and on the contractile cells around the milk glands of the breast. It also sits in the gut, the heart and the blood vessels. In the brain it is found in the amygdala, nucleus accumbens, hypothalamus and prefrontal cortex, exactly the regions that weigh social cues and process fear. Oxytocin does not make you "happy" there; it shifts the weighting: social signals become more salient, threat cues quieter in men. At high concentrations it also hits vasopressin receptors, which touches water balance and blood pressure.

In humans the amygdala effect is the best measured. Spengler and colleagues (Biological Psychiatry 2017) gave 116 healthy men 12, 24 or 48 IU nasally and scanned them at different times: the amygdala response to fearful faces was most clearly damped 45 to 70 minutes after 24 IU, while 48 IU added nothing. Women look different. Lieberz and colleagues (Neuropsychopharmacology 2020) tested 6, 12 and 24 IU in 90 healthy women and found a stronger, not weaker, amygdala response to mildly fearful faces, while both sexes showed more reward-system activity to happy faces. Oxytocin therefore acts in a sex-dependent way. More is not better.

In blood oxytocin is very short-lived. A population analysis after 10 IU intravenously found a distribution half-life of 5.5 minutes and a terminal half-life of 1.2 hours (Nielsen and colleagues, Journal of Clinical Pharmacology 2017); obstetric prescribing information quotes a plasma half-life of a few minutes. The brain effect outlasts the blood level by a wide margin, as the 45 to 70 minute window from Bonn shows. If you use the spray, plan on about an hour of lead time and a few hours of effect, not a day.

At about 1,000 daltons oxytocin is too large and too water-soluble to cross the blood-brain barrier in any meaningful amount. The nose is the attempt to bypass it: along the olfactory and trigeminal nerves there is a route from the upper nasal cavity directly into the cerebrospinal fluid that does not run through the blood. Striepens and colleagues (Scientific Reports 2013) measured this in humans: after 24 IU nasally, oxytocin in plasma peaked at 15 minutes and had fallen again by 75 minutes, whereas in CSF it rose significantly only after up to 75 minutes. The two curves had nothing to do with each other. That fits two separate routes, a fast one across the mucosa into the blood and a slow one along the nerves into the brain.

How much of a spray actually reaches the brain is disputed. Leng and Ludwig (Biological Psychiatry 2016) argue that only a tiny fraction of the nasally applied amount reaches the CSF, while blood levels rise to many times normal and so reach the gut, the heart and the reproductive organs. Quintana and colleagues (Translational Psychiatry 2015) showed the reverse: 8 IU from a breath-powered device that steers the solution into the upper nasal cavity changed the ratings of ambiguous faces more than 24 IU, even though all variants raised plasma levels equally. That argues for a genuine nose-to-brain route independent of blood uptake and for placement in the nose mattering more than the amount.

For practical use this means: keep your head upright, aim the nozzle slightly outwards towards the side of the nostril rather than at the septum. Breathe in gently while spraying instead of sniffing hard. Whatever runs down the throat is digested in the stomach and lost. Do not blow your nose for a few minutes afterwards. With a blocked nose or a cold the uptake is unpredictable, so pick another day.

The starting point was Kosfeld and colleagues (Nature 2005): 24 IU nasally made investors in a trust game hand considerably more money to anonymous trustees without making them more risk-tolerant in a pure gamble. That became the "trust hormone". Within ten years hundreds of studies on empathy, face recognition, pair bonding, autism and schizophrenia followed. Then came the sobering. Nave, Camerer and McCullough (Perspectives on Psychological Science 2015) went through the literature and found that the trust effect did not return in replications, that plasma oxytocin had been measured with questionable methods and that receptor gene variants showed no consistent association with trust in large samples. Walum, Waldman and Young (Biological Psychiatry 2016) added that most studies were too small to separate a real effect from chance.

The imaging and kinetics data are more robust. That 24 IU nasally reach the CSF (Striepens and colleagues 2013), that they damp the amygdala response to fearful faces in men and that 48 IU do no more (Spengler and colleagues 2017) comes from placebo-controlled studies by the same Bonn group. Add to that the finding that women respond differently (Lieberz and colleagues 2020) and a hint from a small Oslo study in 16 men that a small, well-placed dose can achieve more than a large one (Quintana and colleagues 2015). The pattern is consistent: oxytocin changes how social cues are weighted, but the effect is small, context-dependent, sex-dependent and does not follow a simple dose-response curve.

Clinically the balance is thin. A meta-analysis of 42 double-blind trials with 1,922 patients (Bonnieux and colleagues, Neuroscience and Biobehavioral Reviews 2026) found no significant effect on symptoms across disorders, with only a small signal in schizophrenia. In autism, long-term dosing was well tolerated but the benefit remained unclear (Cai and colleagues, Psychiatry and Clinical Neurosciences 2018). In obesity, 24 IU four times daily for eight weeks cut the calories of a test meal by about 150 kcal but did nothing to body weight (Plessow and colleagues 2024). Studies therefore suggest that nasal oxytocin does something measurable in the lab, but that this has not yet turned into a reliable benefit in everyday life. If you use the spray, expect a subtle, individual and by no means guaranteed effect.

• Tolerability in studies: across 38 controlled trials with 1,529 participants, side effects at 18 to 40 IU were no more frequent than under placebo. Participants could not even tell whether they had received oxytocin or placebo (MacDonald and colleagues 2011). The same review lists three case reports of problems with misuse or long-term use. It covers doses below one spray from this bottle.
• Nose and head: burning, sneezing, a runny or dry nose, occasionally headache. In long-term autism trials 14 percent reported nasal discomfort, 7 percent tiredness and 9 percent irritability, all without a difference from placebo (Cai and colleagues 2018). Pause if irritation persists.
• Uterus and breast: oxytocin is the labour hormone. In pregnancy the spray is off limits. Outside pregnancy women may also feel lower abdominal cramps, especially around menstruation. While breastfeeding it triggers milk let-down.
• Circulation and water balance: with rapid intravenous dosing in obstetrics, a drop in blood pressure and a racing heart are known. With large amounts, water retention and low sodium via the vasopressin receptor are known too. Nasal blood uptake is lower, but even the usual 24 IU lift blood levels above the natural range (Leng and Ludwig 2016). A spray with 111 IU does so more strongly. Anyone with heart disease, on blood pressure medication or prone to water retention should leave it alone. No large fluid intake around the dose.
• Gut: nausea, cramps or diarrhoea are possible, the gut carries oxytocin receptors too. In the autism trials diarrhoea occurred in about 5 percent.
• Mind: the effect is not always pleasant. In women oxytocin increased the amygdala response to fearful faces (Lieberz and colleagues 2020). In other work it strengthened favouritism towards one's own group rather than openness towards strangers. If you tend towards anxiety or rumination, start on a day with nothing scheduled.
• Long term: there are no data on months of self-use at this dose. A large controlled trial ran for 24 weeks, but at 48 IU per day, less than half a spray (Sikich and colleagues 2021). Daily amounts close to one spray (80 to 96 IU) ran for eight weeks at most in the studies cited here. So build in breaks and do not spray daily without end.
• Hygiene: the bottle is personal, do not share the nozzle, wipe it after use and put the cap back on.

The spray belongs in the fridge (2 to 8 degrees), not in the freezer and not in the door compartment where the temperature swings every time it opens. Oxytocin in water is heat-sensitive: degradation mainly involves the sulfur bridge between the two cysteine residues and speeds up with every degree. Because oxytocin ampoules for obstetrics lose potency in warm countries without a cold chain, the Groningen group around Avanti (AAPS Journal 2011) worked on exactly this problem. They found stabilisers made of citrate and divalent metal ions that slow the breakdown. This spray is plain saline without such stabilisers, so refrigeration takes the place of formulation chemistry. Only 0.4ml of the 5.4ml is bacteriostatic water, so the preservative it contains is heavily diluted and holds back germs only to a limited extent.

Once opened, the solution keeps for several months in the fridge without meaningful loss of potency, like the reconstituted vial. A few hours at room temperature, in the post or in a bag, do it no harm; a day in a warm car is another matter. Protect from light by leaving the bottle in its box. On paper the bottle holds 54 sprays. About 50 remain after priming the pump. At one spray per day it is empty after a little over seven weeks, at 2 to 3 dosing days per week after roughly four to six months. With infrequent use hygiene matters all the more: wipe the nozzle after every use, put the cap back on and only insert the nozzle just inside the nostril.

Before first use, prime the pump once or twice into the air until a fine mist appears. After that, prime again only after a longer break. If the solution turns gel-like, lumpy or smells different, stop using it. Slight cloudiness on its own is not a reason. If you do not need the bottle for a while, leave it closed and cold and give it a brief shake before the next use, that does the peptide no harm.